West China Hospital, Sichuan University
chengdu, China (People's Republic)
Feng wang ，Doctor，Archiater，Department of Head and Neck Oncology, West China Hospital, Sichuan University
Capital Medical University Hospital, Beijing Medical University Hospital, Tohoku University Hospital, Japan, from 2006 to West China Hospital, Sichuan University to date.
2001-2006 Department of Radiotherapy, Tohoku University Hospital, Japan, engaged in basic research in radiobiology and tumor molecular biology; participated in the cell panel of the Japan-American 21st Century Medical Engineering Research Project and served as the main researcher to study DNA damage and repair, gene mutation and XPG-gene variation characteristics.
1. Guangdong Provincial Department of Science and Technology Major Science and Technology Special Project for the R & D of molecular diagnostic products for real-time tumor monitoring based on liquid biopsy, with a total fund of 20 million yuan. My sub-project is mainly studied at 500,000 yuan on May 19, 2019.
2. Study on the kinetics and mechanism of vascular normalization by endostatin in tumor-bearing mice The first main research institute of the Ministry of Science and Technology, 310,000. 2010-2012.
3. To observe the relationship between Taixinsheng combined with chemoradiotherapy and IDH1/2, MGMT, 1p19q, TERT, BRAF genotypes in the treatment of recurrent high-grade glioma by 80,000 Chinese Professional Committee of Neuro-Oncology, the main research institute of Anti-cancer Association. 2015-2018.
4. CTCs and their EGFR signaling pathways of Professional Committee of Chinese Anti-Cancer Association in the treatment of advanced head and neck squamous cell carcinoma with Erbitux, efficacy prediction and drug resistance mechanism of 50,000 main research. 2016-2018.
5, the mechanism of SARI gene expression inactivation in colon cancer Young Science Foundation project 250,000 yuan, the first main research. 2016-2018